MKSI Stock Study (1-13-23)

I recently did a stock study on MKS Instruments (MKSI) with a closing price of $99.37.

This medium-sized company has grown sales and EPS at rates of 20% and 29.5% per year since 2013. Historical sales and EPS are up and somewhat straight/parallel as EPS has had more of a rocky ride (down in 2016, 2019, and projected 2022). PTPM over the last 10 years has gone up and down between 8.9% and 23.4% with a 5-year average of 19.4%. This is better than peer (stated as TRMG, CGNX, and TDY) and industry averages. ROE over the last five years has averaged 17.3% and is also better than peer and industry averages.

MKSI had no debt until 2016. Over the last five years, debt to capital has averaged 24.8% and been below peer and industry averages. This has all changed with the recent $5.1B acquisition of Atotech. According to M*, MKSI has Current and Quick ratios of 2.8 and 1.6, respectively. While these are healthy, Interest Coverage is a lukewarm 6.5. Value Line lists the latter over 25, but I don’t believe this takes into account the acquisition involving issuance of $4B in debt and 11M shares, which will dilute future EPS.

From CFRA, MKSI is:

     > a leading supplier of components and subsystems that measure, control, power, and
     > monitor critical parameters of semiconductors and other advanced manufacturing
     > processes. The majority of MKSI’s sales are derived from products sold to
     > semiconductor capital equipment manufacturers and semiconductor device manufacturers.
     > The company’s products are used in the chipmaking process, including depositing thin
     > films of material onto silicon wafer substrates and etching and cleaning circuit patterns.”

I will assume long-term annualized sales growth of 7% based on the following:

• CNN Business projects 20.7% growth for 2023 and 13% growth per year for 2022-2024 (based on eight analysts).
• YF projects YOY 17.2% and 7% growth for ’23 and ’24, respectively (nine analysts).
• Zacks projects YOY 17.2% and 7.3% growth for ’23 and ’24, respectively (3).
• Value Line projects 15.7% growth per year from ’21-’26.
• CFRA projects 11.7% and 12.4% growth per year for ’21-’23 and ’21-’24, respectively.

I will assume long-term annualized EPS contraction of 1% based on the following:

• CNN Business reports contraction of 18.7% YOY and 35.5% per year for ’23 YOY and ’22-’24, respectively (based on eight analysts).
• MarketWatch projects annualized contraction of 34.9% and 13.9% from ’22-’24 and ’22-’25, respectively (10 analysts).
• Nasdaq.com projects contraction of 49.3% YOY and 14.8% per year for 2023 and ’22-’24, respectively (5, 5, and 4 analysts for ’22, ’23, and ’24).
• YF projects YOY contraction of 18.7% and 48.8% for ’22 and ’23, respectively, along with 10.2% contraction per year for the next five years.
• Zacks projects 19.2% and 49.3% YOY contraction for ’22 and ’23, respectively (5).
• Value Line projects annualized contraction of 3.5% from ’21-’26.
• CFRA projects annualized contraction of 32.9% and 15% for ’21-’23 and ’21-’24, respectively, with a 3-year EPS growth projection of 2% per year.

I project a future High P/E of 17. High P/E has averaged 25.2 over the last five years with 17.4 being the low end of the last-10-year range (2015).

I project a future Low P/E of 9. Low P/E has averaged 13.3 over the last five years, but 24.6 in 2019 seems to be an upside outlier. Without that, the 5-year average drops to 10.5. I was tempted to use 7.5, but that seems too extreme. 7.5 would eclipse the low end of the last-10-year range (7.9 in 2018) and result in a projected low price of $57.50. This would undercut the 2020 low and be 42% below the previous closing price.

The projected low price based on these inputs is $69, which is 30% below the previous close.

All this results in an U/D ratio of 2, which puts MKSI in the Hold zone down to $91.80. CAR (using forecast High P/E) is 10.7% and PAR (using forecast average P/E) is 5.1%. For me, the latter is too low for a medium-sized company. Payout Ratio for the last five years averaged 15%. I have estimated 10% as 2019’s 31.4% seems like an upside outlier.

I look to Member Sentiment to assess margin of safety. Averages of 239 studies over the past 90 days indicate projected sales growth, EPS growth, High P/E, Low P/E, and Payout Ratio to be 10.1%, 8%, 19.4, 10.9, and 17.5%, respectively. I’m lower across the board and much lower on EPS. Analysts project nothing even close to 8%, which leaves me rather puzzled on that one. Member Sentiment also averages ~$75 for the projected low price, which is higher than mine.

I see a lot of risk with this stock. The debt taken on for Atotech seems to have basically set this company back five years. While saying the acquisition should result in longer-term synergies, Value Line projects long-term EPS growth to be even more negative than my -1%. If the synergies don’t materialize, then MKSI will be left with quite a bill to pay.

The best-case scenario would be resumption of MKSI’s previous EPS trajectory. Because I don’t know if this will come to fruition, I believe the healthy margin of safety is warranted.